TABLE 3.

The clinical research of c-Met inhibitors in non-digestive system cancers.

Cancer	Agents	Phase	Primary results	References
Melanoma	Cabozantinib	II	Cabozantinib vs. temozolomide or dacarbazine: PFS: 60 vs. 59 days (P = 0.964; HR = 0.99). OS: 6.4 vs. 7.3 months (P = 0.580; HR = 1.21). Cabozantinib demonstrated no improvement in PFS but an increase in toxicity.	Luke et al., 2020
Breast cancer with bone metastases	Cabozantinib	II	Bone scans improved in 38% of patients and remained stable in an additional 12% for a minimum duration of 12 weeks. PFS was 4.3 months and OS was 19.6 months.	Xu et al., 2020
Papillary renal cell carcinoma	Savolitinib vs. sunitinib	III	PFS: 7.0 months (95% CI, 2.8–not calculated) for savolitinib and 5.6 months (95% CI, 4.1–6.9) for sunitinib. Savolitinib demonstrated encouraging efficacy with fewer grade 3 or higher adverse events.	Choueiri et al., 2020
Non-Small Cell Lung Cancer	Tepotinib	II	The response rate of liquid-biopsy group (n = 66) and tissue-biopsy group (n = 60) were 48% and 50%, respectively. Median duration of response was 11.1 months.	Paik et al., 2020
	Tivantinib + erlotinib	III	Erlotinib + tivantinib vs. erlotinib + placebo; PFS: 13.0 vs. 7.5 months; OS: 25.5 vs. 20.3 months. Erlotinib + tivantinib was tolerable and showed improved efficacy over erlotinib monotherapy.	Scagliotti et al., 2018
Medullary thyroid cancer	Cabozantinib	III	Cabozantinib vs. placebo: PFS: 11.2 vs. 4.0 months; ORR: 28 vs. 0%.	Elisei et al., 2013